EHA 2026: Combination Therapy Provides Durable QoL and Physical Function Benefits in Treatment-Naïve CLL
At EHA 2026, results from the phase 3 AMPLIFY trial showed that time-limited acalabrutinib-based combinations were associated with greater and more durable improvements in quality of life and physical functioning than chemoimmunotherapy.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
